CagriSema Weight Loss Results: What the Phase 3 Data Actually Shows

Important: We are not doctors. Everything in this article is based on published research and publicly available clinical trial data. It is not medical advice. Talk to your physician before changing any medication or health protocol.

---

CagriSema Weight Loss Results: What the Phase 3 Data Actually Shows

A new combination drug just posted Phase 3 interim data that has the weight loss research community paying attention.

CagriSema showed results that, if they hold through final analysis, would push past what tirzepatide currently achieves. That is a meaningful claim. Tirzepatide set the bar at around 20-22% body weight reduction in its landmark SURMOUNT trials. No approved drug has cleared that mark yet.

CagriSema may be the first one that does.

Here is what the data shows, what the mechanism is, and what this means for people following the next generation of weight loss research.

---

Key Takeaways

• CagriSema combines cagrilintide (amylin analog) with semaglutide 2.4 mg
• Phase 3 interim data suggests weight loss that may exceed tirzepatide's current ceiling
• The drug works through a dual mechanism: GLP-1 receptor activation plus amylin pathway signaling
• It is not FDA-approved and is still in trials as of March 2026
• Muscle preservation during GLP-1 therapy remains an open question for CagriSema and all GLP-1 drugs

---

What Is CagriSema?

CagriSema is a fixed-ratio combination drug developed by Novo Nordisk. It pairs two active compounds:

Cagrilintide is a long-acting amylin analog. Amylin is a hormone produced in the pancreas alongside insulin. It plays a role in satiety signaling, slowing gastric emptying, and glucagon suppression. Cagrilintide is designed to mimic and extend those effects.

Semaglutide 2.4 mg is the same active ingredient in Wegovy, the FDA-approved weight management medication. At the 2.4 mg weekly dose, semaglutide acts on GLP-1 receptors in the brain and gut to reduce appetite and food intake.

By combining these two compounds into a single weekly injection, Novo Nordisk is targeting two separate weight-regulating pathways at once.

CagriSema is currently being evaluated in the REDEFINE clinical trial program. It is not FDA-approved and is classified as an investigational drug. The information below comes from publicly available trial data and interim results.

---

How CagriSema Works: The Dual Mechanism

Most GLP-1 drugs work through one primary pathway: the glucagon-like peptide-1 receptor. They tell the brain you are full, slow gastric emptying, and reduce caloric intake. That mechanism has proven powerful. Semaglutide alone produces roughly 15-17% body weight reduction at 2.4 mg.

CagriSema adds a second layer.

The amylin pathway runs parallel to the GLP-1 pathway. When amylin signals properly, it reinforces satiety, suppresses appetite through different neural circuits, and helps regulate post-meal glucose spikes. Research suggests the two pathways may work together in ways that are additive rather than simply redundant.

Think of it this way: GLP-1 agonism tells the brain one message about fullness. Amylin agonism sends a related but distinct signal through a different channel. Using both at once may produce a stronger combined effect than either produces alone.

This is also the logic behind tirzepatide's success. Tirzepatide acts on both GLP-1 and GIP receptors. That dual-receptor approach outperformed single-receptor semaglutide in head-to-head trials. CagriSema follows the same principle but uses a different second pathway (amylin instead of GIP).

---

Phase 3 Results: What the Data Shows

The REDEFINE trial program for CagriSema is ongoing. Novo Nordisk released interim data in early 2026 that has drawn significant attention from the research community.

The interim results suggest mean body weight reductions in the range that would surpass tirzepatide's current benchmark of approximately 20-22% in the SURMOUNT-1 trial.

We want to be precise about what "interim data" means here. This is not final trial data. Interim analyses are snapshots taken before a trial concludes. They can shift as more patient data accumulates, dropout rates are accounted for, and longer-term outcomes become clear. Final trial data could look different, better or worse, than interim numbers suggest.

That said, research-focused communities have taken note. Discussion across GLP-1 research forums reflects genuine interest in whether CagriSema could represent a meaningful step forward beyond tirzepatide in terms of raw weight loss percentage.

What we can say based on available data:

• Phase 2 data for CagriSema published in The Lancet showed approximately 15.6% body weight reduction over 32 weeks at the highest dose combination, which was stronger than semaglutide or cagrilintide alone in the same trial
• The Phase 3 interim data suggests the trajectory has continued, with reports pointing toward weight loss percentages in the mid-to-high twenties at the one-year mark
• The trial population included adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity, similar to the Wegovy and Zepbound trial populations

Full Phase 3 results are expected later in 2026. FDA submission would follow a successful trial completion.

For the most current published data, we recommend checking the ClinicalTrials.gov REDEFINE trial listing and PubMed for cagrilintide semaglutide.

---

CagriSema vs Tirzepatide vs Semaglutide: How They Compare

Here is how the three compounds stack up based on published trial data:

Drug	Mechanism	Peak Weight Loss (Trial Data)	Status
Semaglutide 2.4 mg (Wegovy)	GLP-1 agonist	~15-17% (STEP 1 trial)	FDA-approved
Tirzepatide 15 mg (Zepbound)	GLP-1 + GIP dual agonist	~20-22% (SURMOUNT-1)	FDA-approved
CagriSema (investigational)	GLP-1 + amylin dual agonist	Phase 3 interim: reports of 25%+	Phase 3 / Investigational

A few important notes on this comparison:

Trial populations differ. Direct head-to-head comparisons between drugs are rare. The numbers above come from separate trials with different patient groups, follow-up periods, and dropout handling. They are useful for general reference but should not be treated as a controlled comparison.

Semaglutide is the shared ingredient. CagriSema contains semaglutide 2.4 mg, the same as Wegovy. The additional weight loss in CagriSema trials comes from the cagrilintide component adding its amylin-pathway effects on top.

Side effect profiles may differ. GI side effects (nausea, vomiting, diarrhea) are common across all GLP-1 drugs. Amylin analogs have their own tolerability considerations. Cagrilintide monotherapy trials showed injection site reactions as a notable side effect. The combined CagriSema data on side effects will need to be assessed in full trial results.

---

The Muscle Preservation Question

One of the most discussed topics in GLP-1 research right now is muscle loss during rapid weight reduction.

When people lose weight quickly on GLP-1 drugs, a portion of that weight loss comes from lean mass, not just fat. The degree of lean mass loss varies by individual and is influenced by protein intake, resistance training, and rate of weight loss.

This concern has been labeled informally as "Musclezempic" in online communities, a reference to the muscle wasting some users report.

CagriSema has not yet published comprehensive body composition data from Phase 3. The question of how cagrilintide's mechanism interacts with lean mass preservation is open.

Separately, other researchers are working on peptides specifically designed to protect or build muscle during GLP-1 therapy. One example is research coming out of China on a four-strand peptide GLP-1 compound designed with muscle protection as a design goal. That research is at early stages and well before human trials.

For anyone on any GLP-1 therapy, the current best-evidence approach to lean mass preservation includes:

• Adequate protein intake (research in this population generally supports 1.2-1.6g per kg of body weight)
• Resistance training during the weight loss period
• Working with a physician to monitor body composition if possible

This is an area where the science is actively developing. We will update our coverage as CagriSema body composition data becomes available.

---

What Is Happening With Other Next-Generation Weight Loss Drugs?

CagriSema is not the only compound researchers are watching closely.

Retatrutide, a triple-agonist targeting GLP-1, GIP, and glucagon receptors, showed Phase 2 results with up to 24.2% body weight reduction. As of March 2026, Polymarket prediction markets place FDA approval odds for retatrutide at approximately 18%, up from 10% earlier this year. That remains a relatively low probability, reflecting how unpredictable regulatory timelines are.

The GLP-1 pipeline is unusually active right now. Multiple compounds targeting different combinations of metabolic receptors are in trials simultaneously. The competitive landscape means that even if CagriSema succeeds, it will likely face competition from other approved drugs within a few years.

For current readers: the only FDA-approved injectable weight loss medications are semaglutide (Wegovy) and tirzepatide (Zepbound). Any other compound mentioned in this article is investigational and not available as a prescription medication.

---

What This Means for the Future

If CagriSema's Phase 3 data holds through final analysis, it would be a meaningful development for several reasons.

First, it would confirm that layering a second metabolic pathway on top of GLP-1 activation continues to produce incremental weight loss gains. That validates the dual-agonist and combination-drug approach more broadly.

Second, it would give prescribers another option for patients who have tried semaglutide or tirzepatide and want additional weight loss or have tolerability issues with existing options.

Third, it raises the question of where the ceiling actually is. GLP-1 drugs have consistently outperformed what researchers expected. The field keeps moving.

The practical timeline: if Phase 3 results are published in late 2026 and the data supports an FDA submission, review would likely take 12-18 months after submission. A realistic commercial availability date, if everything goes well, would be 2028 at the earliest.

That is still a long runway. For people researching options today, tirzepatide remains the highest-efficacy FDA-approved weight loss medication available.

---

Frequently Asked Questions {#faq}

What is CagriSema and how does it work?

CagriSema is an investigational combination drug from Novo Nordisk. It pairs cagrilintide (an amylin analog) with semaglutide 2.4 mg (the same ingredient in Wegovy). The two compounds target different biological pathways involved in appetite and weight regulation. CagriSema is not FDA-approved and is currently in Phase 3 clinical trials.

How does CagriSema compare to tirzepatide for weight loss?

Based on available interim Phase 3 data, CagriSema appears to produce greater weight loss than tirzepatide's current benchmark of approximately 20-22% body weight reduction in the SURMOUNT-1 trial. However, these are interim results from an ongoing trial and direct head-to-head comparison data does not exist yet. Final trial results are expected later in 2026.

When will CagriSema be FDA-approved?

CagriSema has not been submitted for FDA approval as of March 2026. Final Phase 3 trial results are expected in late 2026. If the data supports a submission and the review process proceeds without major issues, commercial availability would likely be 2028 at the earliest. No approval date has been announced.

What are the side effects of CagriSema?

Published Phase 2 data showed GI side effects (nausea, vomiting, diarrhea) similar to other GLP-1 medications. Injection site reactions were also reported, consistent with cagrilintide monotherapy data. Full Phase 3 safety and tolerability data will be available with the final trial results. Always discuss potential side effects with a qualified healthcare provider.

Is CagriSema better than semaglutide (Wegovy)?

CagriSema contains semaglutide 2.4 mg as one of its two components. The additional cagrilintide component appears to add meaningful weight loss beyond what semaglutide alone produces. Phase 2 data showed CagriSema outperforming semaglutide monotherapy in the same trial. Whether that advantage holds at scale across a diverse patient population is what Phase 3 is designed to confirm.

Can I get CagriSema right now?

No. CagriSema is an investigational drug available only through clinical trials as of March 2026. You cannot get a prescription for it. If you are interested in participating in the REDEFINE trial program, check ClinicalTrials.gov for open enrollment sites.

---

Related Reading

• GLP-1 Peptides: The Complete Guide — our pillar page covering how the full class of GLP-1 medications works
• Semaglutide vs. Liraglutide: A Research Comparison — how two generations of GLP-1 drugs compare
• The Effect of Weight Loss on Clinical Outcomes — what the research says about downstream health effects

---

Medical Disclaimer

The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The editorial team shares published research findings, not medical recommendations. CagriSema is an investigational drug and is not FDA-approved for any indication as of the publication date of this article.

---

Sources

1. REDEFINE trial program — ClinicalTrials.gov — Novo Nordisk Phase 3 program for CagriSema
2. Cagrilintide + semaglutide combination Phase 2 results — The Lancet, 2023 — Phase 2 REDEFINE 1 data showing 15.6% weight reduction at 32 weeks
3. Tirzepatide SURMOUNT-1 trial — New England Journal of Medicine, 2022 — Tirzepatide Phase 3 data showing up to 22.5% weight reduction
4. Semaglutide STEP 1 trial — New England Journal of Medicine, 2021 — Semaglutide 2.4 mg Phase 3 data showing 14.9% weight reduction
5. Amylin physiology and pharmacology — PubMed review — Background on amylin's role in satiety and metabolic regulation
6. Retatrutide Phase 2 results — New England Journal of Medicine, 2023 — Triple agonist Phase 2 data showing up to 24.2% weight reduction

---

Schema Markup

{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "Organization",
      "@id": "https://peptidenerds.com/#organization",
      "name": "Peptide Nerds",
      "url": "https://peptidenerds.com",
      "logo": {
        "@type": "ImageObject",
        "url": "https://peptidenerds.com/logo.png"
      },
      "sameAs": [
        "https://instagram.com/fatmaninthearena"
      ]
    },
    {
      "@type": "Article",
      "@id": "https://peptidenerds.com/blog/cagrisema-weight-loss-phase-3-results#article",
      "headline": "CagriSema Weight Loss Results: What the Phase 3 Data Actually Shows",
      "datePublished": "2026-03-10T08:00:00-05:00",
      "dateModified": "2026-03-10T08:00:00-05:00",
      "author": {
        "@type": "Person",
        "name": "Alejandro Reyes",
        "url": "https://peptidenerds.com/about"
      },
      "publisher": {
        "@id": "https://peptidenerds.com/#organization"
      },
      "description": "CagriSema just posted interim Phase 3 data. We break down what it shows, how it compares to tirzepatide and semaglutide, and what comes next.",
      "mainEntityOfPage": {
        "@type": "WebPage",
        "@id": "https://peptidenerds.com/blog/cagrisema-weight-loss-phase-3-results"
      }
    },
    {
      "@type": "FAQPage",
      "@id": "https://peptidenerds.com/blog/cagrisema-weight-loss-phase-3-results#faq",
      "mainEntity": [
        {
          "@type": "Question",
          "name": "What is CagriSema and how does it work?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "CagriSema is an investigational combination drug from Novo Nordisk. It pairs cagrilintide (an amylin analog) with semaglutide 2.4 mg (the same ingredient in Wegovy). The two compounds target different biological pathways involved in appetite and weight regulation. CagriSema is not FDA-approved and is currently in Phase 3 clinical trials."
          }
        },
        {
          "@type": "Question",
          "name": "How does CagriSema compare to tirzepatide for weight loss?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Based on available interim Phase 3 data, CagriSema appears to produce greater weight loss than tirzepatide's current benchmark of approximately 20-22% body weight reduction. However, these are interim results from an ongoing trial and direct head-to-head comparison data does not exist yet. Final trial results are expected later in 2026."
          }
        },
        {
          "@type": "Question",
          "name": "When will CagriSema be FDA-approved?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "CagriSema has not been submitted for FDA approval as of March 2026. Final Phase 3 trial results are expected in late 2026. If the data supports a submission and review proceeds without major issues, commercial availability would likely be 2028 at the earliest."
          }
        },
        {
          "@type": "Question",
          "name": "What are the side effects of CagriSema?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Published Phase 2 data showed GI side effects (nausea, vomiting, diarrhea) similar to other GLP-1 medications. Injection site reactions were also reported, consistent with cagrilintide monotherapy data. Full Phase 3 safety data will be available with final trial results. Always discuss potential side effects with a qualified healthcare provider."
          }
        },
        {
          "@type": "Question",
          "name": "Is CagriSema better than semaglutide (Wegovy)?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "CagriSema contains semaglutide 2.4 mg as one of its two components. The additional cagrilintide component appears to add meaningful weight loss beyond what semaglutide alone produces. Phase 2 data showed CagriSema outperforming semaglutide monotherapy in the same trial. Phase 3 results will confirm whether that advantage holds across a larger, more diverse patient population."
          }
        },
        {
          "@type": "Question",
          "name": "Can I get CagriSema right now?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "No. CagriSema is an investigational drug available only through clinical trials as of March 2026. You cannot get a prescription for it. If you are interested in participating in the REDEFINE trial program, check ClinicalTrials.gov for open enrollment sites."
          }
        }
      ]
    }
  ]
}